Oxygen Biotherapeutics ousts CEO Stern "for cause", following internal investigation
This article was originally published in Scrip
Executive Summary
Oxygen Biotherapeutics disclosed in a regulatory filing with the US Securities and Exchange Commission that it has dismissed its CEO Chris Stern "for cause" in connection with a probe conducted by the company itself. The board, meanwhile, has named its chief financial officer, Michael Jebsen, as interim CEO while a search is conducted for a permanent replacement.